Pneumococcal conjugate vaccine 14-valent (adsorbed) - Biological E Limited
Alternative Names: 14-valent pneumococcal conjugate vaccine (thiomersal free)Latest Information Update: 12 Dec 2022
At a glance
- Originator Biological E Limited
- Class Conjugate vaccines; Pneumococcal vaccines; Polysaccharides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Pneumococcal infections
Most Recent Events
- 12 Dec 2022 Pneumococcal conjugate vaccine 14-valent (adsorbed) is still in phase III trials for Pneumococcal infections (Prevention, In infants) in India (IM) (Biological E Limited pipeline, December 2022) (CTRI/2020/02/023129)
- 12 Dec 2022 Biological E Limited completes enrolment in phase III trial in Pneumococcal infections (Prevention, In infants) in India (IM) before December 2022 (CTRI/2020/02/023129)
- 29 Sep 2020 Pneumococcal conjugate vaccine 14-valent (adsorbed) is still in phase II trials for Pneumococcal infections (Prevention, In volunteers, In children, In adults, In adolescents) in India (CTRI/2017/11/010387)